In another study, a tumor-targeting ligand (EphA2) was conjugated to microspheres blended with PCL and PLGA, demonstrating excellent therapeutic efficacy by successfully inhibiting local tumor regrowth in triple-negative breast cancer through prolonged drug release for more than 90 days [77]. The gene discussed is EPHA2; the disease is neoplasm.